EMA’s envisaged risk-based and human-centric approach to regulate AI

Written By

christian lindenthal module
Christian Lindenthal, LL.M.

Partner
Germany

As a partner in our Munich team, I advise clients from the life sciences sector on matters at the interface between IP, unfair competition and regulatory law. I am a member of our Intellectual Property Practice Group as well as our Life Sciences and Healthcare Sector Group.

nils loelfing module
Dr. Nils Lölfing

Counsel
Germany

I am a counsel in our Technology & Communications Sector Group. I provide pragmatic and solution-driven advice to our clients on all issues around data and information technology law, with a strong focus on and experience with AI and machine learning projects.

hester borgers Module
Hester Borgers

Senior Associate
Netherlands

As a senior associate in our Intellectual Property Group in Amsterdam, I specialise in life sciences patent law and life sciences regulatory.

Bird & Bird’s international life sciences and healthcare team is at the forefront of the legal developments with regard to AI and the life sciences sector. This article is part of our new series, which will highlight different legal angles to consider when implementing AI in the life sciences and healthcare industry.

Latest insights

More Insights
mountain scape

European Union Artificial Intelligence Act Guide

Nov 06 2024

Read More
Curiosity line green background

Transforming A Brand into A Global Business – what to consider from a legal perspective

Nov 05 2024

Read More
camera

Landmark decision by the District Court of Hamburg on text and data mining exceptions (Kneschke v. Laion)

Nov 05 2024

Read More